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T-Lymphocyte Subset Studies to Monitor Patients with AIDS and
AIDS-Related Complex
Hajime Hayashi, PhD,* Eugene Mezger, MD,+ Michael J. Deegan, MD,* Evelyn J.
Fisher, MD,* and Norman Markowitz, MD*
Multiple specimens from 124 patients from our clinic were evaluatedfor T4IT8 cell ratio over three to
28 months. Twenty-nine of 30patients with the acquired immunodeficiency syndrome (AIDS), 58 of 71
patients with AIDS-related complex (ARC), and four of 23 patients at risk showed initial T4IT8 cell
ratios of less than 0.8. which either remained unchanged or decreased. Seventeen of 23 AIDS patients
and two of20 ARC patients with a consistently low ratio (0.3 orless) died during the follow-up period.
This indicated that the severity of disease could be predicted by periodical T4IT8 cell ratio studies.
These serial studies appeared to be valuable in monitoring the course ofpatients with AIDS, ARC, and
the human immunodeficiency virus infection and also in evaluating the effects of available drug
treatments. (Henry Ford Hosp Med J 1987:35:30-2)

he most commonly used laboratory tests for evaluating patients with the acquired immunodeficiency syndrome
(AIDS) are the anti-human immunodeficiency vims (anti-HlV)
antibody test (1) and the subpopulation study of T-lymphocytes
(helper/suppressor or T4/T8 cell ratio) (2), [Naming of the
human immunodeficiency virus (HIV) for lymphadenopathyassociated vims (LAV), human T-cell lymphotropic vims type
III (HTLV-III), immunodeficiency-associated virus (IDAV),
and AIDS-associated retrovirus (ARV) was proposed by the
subcommittee and endorsed by the executive committee of the
Intemational Committee on the Taxonomy of Vimses (3).] Since
the etiological agent of AIDS was established (4-6), the antiHIV test has been used at blood donor stations to screen for the
HIV-infected donor (7,8). It is also used at clinics as a diagnostic
tool for patients with AIDS or AIDS-related complex (ARC).
This serologic test can detect the antibody which indicates past
or present infection with HIV, This test, however, is of limited
value in the follow-up or prognosis of disease, because when a
patient tests positive, the antibody usually stays positive thereafter. The relationship of antibody levels to the course of disease
is not established.
Serial study of T4/T8 cell ratio is useful for monitoring the
immunological status of a given patient over time. We are reporting an application of the T4/T8 cell ratio in the prognosis of
patients with AIDS and ARC.

T

Clinical Specimens
For purposes of clinical classification, the following criteria
were adopted. The definition of AIDS was based on criteria from
the Centers for Disease Control (9). ARC was defined to include
those patients who were anti-HIV antibody positive by both enzyme immunoassay (1) and Westem blot technique (10) and who
did not have AIDS but displayed the symptoms, signs, or laboratory abnormalities consistent with HIV infections. At-risk
patients were HIV antibody positive without clinical manifestations of disease.
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The 124 patients studied were classified into three groups:
1) 30 AIDS patients, 2) 71 ARC patients, and 3) 23 at-risk patients. Blood specimens from these patients were evaluated over
three to 28 months (average 8.7 months).

Methods
Testing for anti-HIV antibody
Antibody to HIV was measured with the Abbott HTLV-III enzyme immunoassay (Abbott Laboratories, North Chicago, IL)
(1). Reactive semm specimens were tested by the Westem blot
technique for confirmation (10).

Testing for T-lymphocyte subset
T-lymphocyte subset study was performed by direct immunofluorescence on a flow cytometer (Coulter EPICS V) with use
of commercially available monoclonal antibodies (OKTll for
total T, OKT4 for T-helper, and 0KT8 for T-suppressor cells
from Ortho Pharmaceuticals, Raritan, NJ) (11). The buffy coat
from heparinized blood was first reacted with each monoclonal
antibody conjugated with fluorescence isothiocyanate for
30 minutes in an ice bath. After eliminating erythrocytes by
a lysing reagent, tagged cells were fixed with 0.5% paraformaldehyde before testing. The percent of positive cells for
each subset was measured on "gated" lymphocytes by flow
cytometer The absolute count ofeach T-cell population was also
calculated.
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Results
The normal ranges of T-lymphocyte subpopulations established from 84 "normal" individuals at our laboratory are
summarized in Table I . A T4/T8 cell ratio lower than 0.8 was
considered "low" and 0,3 or less "extremely low."
Table 2 summarizes a comparison of T4/T8 cell ratio and antiHIV antibody in 124 patients (30 AIDS patients, 71 ARC patients, and 23 at-risk patients). The HI V-antibody test detected
exposure to the vims. When patients tested positive, they usually stayed positive thereafter, regardless of the clinical course.
On the other hand, the T4/T8 cell ratio can stratify the patients
by a low (0.4 to 0.7) or extremely low (0.3 or less) ratio. These
values were subsequently shown to be related to the clinical
course.
Table 3 shows the follow-up study of these patients by T4/T8
cell ratio. A total of 377 specimens from 124 patients were submitted (average 3.0 specimens per patient). The T4/T8 cell ratio
in those patients with low and extremely low ratios did not
change. However, some patients who had an initially normal
ratio fell to low or extremely low ratios during the follow-up
period. One AIDS patient, nine ARC patients, and six at-risk
patients demonstrated a reversal of T4/T8 cell ratios on subsequent specimens. None of the patients improved the ratio on the
subsequent specimens. Seventeen of 23 AIDS patients and two
of 20 ARC patients with a consistently low ratio (0.3 or less)
died during the follow-up period. This indicated that the severity
of disease could be predicted by an extremely low T4/T8 cell
ratio.
The follow-up data for two patients are shown in Table 4 as
examples. Decrease of the absolute count of T-lymphocytes was
also evident with extremely low cell ratios, although the two
were not always associated.

Discussion
Enzyme immunoassay for anti-HIV antibody is a simple test
to detect a patient's exposure to the virus and is sensitive for
screening at-risk patients. The T-lymphocyte subset study
reveals the degree of suppression in T-lymphocytes.
The simultaneous anti-HIV antibody and T4/T8 cell ratio assays are most helpful for the stratification of patients with AIDS
or ARC. These patients were found to have low or extremely low
T4/T8 cell ratios. The patients with extremely low ratios had a
poor prognosis. Patients with HIV antibody and normal T4/T8
cell ratios were usually in the asymptomatic at-risk group.
Serial testing of the T4/T8 cell ratio is useful in monitoring
the changing immunological status of the following groups:
1) parients with ARC (not full-blown AIDS); 2) individuals
at risk (anti-HIV antibody positive by routine screening, but
without symptoms); and 3) patients with HIV under antiviral
therapy.
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Table 1
Normal Ranges for T-Lymphocyte Subpopulations (n = 84)

T i l (total)
T4 (helper)
T8 (suppressor)
T4/T8 cell
ratio

Ranges
Mean ± Standard Deviation
Standard
Mean '/< Deviation Normal %
(absolute count)
(530-27 lO/mm')
7.2
57.3-86.7
72.3
49.5
8.1
33.4-65.6
(400-1730/mmi)
26.8

6.9

13.1-40.6

2.0

0.6

0.8-3.2

(150-990/mm3)

Table 2
Comparison of Helper (T4) and Suppressor (T8)
T-Lymphocyte Ratio and Anti-HIV Antibody in Three
Patient Groups
T4/T8 Cell
Ratio
Normal: s= 0.8
Low: 0.4-0.7
Extremely low: 0.3
Total: 124 patients

Number of Patients (Anti-HIV Antibody Positive)
AIDS
ARC
At Risk
13 (7)
19(6)
1 (1)
6 (4)
38(35)
4(2)
23 (23)
20(18)
0
30 (28)
71 (60)
23 (8)

Table 3
Follow-up Study of Helper (T4) and Suppressor (T8)
T-Lymphocyte Ratio in Three Patient Groups
Initial
3= 0.8
0.4-0.8

T4/T8 Cell Ratio
Subsequent Change
No change
i
No change

t ori
=s 0.3
Total: 124

Number of Patients (Deceased)
AIDS
ARC
At Risk
0
4
13
1
9
6
31
4
3
3
7
0
23 (17)
20(2)
0
30 (17)
71 (2)
23

i = decreased.
t or I = fluctuated within abnormal range.

Table 4
Follow-up Study
TH
Example 1: Patient with AIDS*
1st specimen
6 months
10 months
Example 2: Patient with ARC*
1 st specimen
8 months

T-Lymphocyte Subset
T4
T8

81%
(I318)t
74%
(783)
64%
(922)

40%
(640)
9%
(95)
8%
(50)

47%
(753)
58%
(614)
50%
(720)

57%
(629)
84%
(428)

3%
(33)
1%
(5)

59%
(658)
66%
(337)

T4/T8
0.85
0.15
0.16
0.05
0.02

8 months (deceased)
*Both patients were anti-HIV positive.
tAbsolute count.

T-Lymphocyte Studies in AIDS—Hayashi et al

31

3. Brown F. Human immunodeficiency vims. Science I986;232:I486.
4. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic
retrovirus from a patient at risk for acquired immune deficiency syndrome
(AIDS). Science 1983;220:868-71.
5. Popovic M, Samgadharan MG, Read E, Gallo RC. Detection, isolation,
and continuous production of cytopathic retrovimses (HTLV-III) from patients
with AIDS and pre-AIDS. Science 1984;224;497-500.
6. Levy JA, Hoffman AD, Kramer SM, Landis JA. Shimabukuro JM, Oshiro
LS, Isolation of lymphocytopathic retrovimses from San Francisco patients with
AIDS. Science 1984;225:840-2,
7. Centers for Disease Control. Results of human T-lymphotropic vims type
III test kits reported from blood collection centers—United States, April 22May 19. 1985. MMWR 1985;34:375-6.

32

Henry Ford Hosp Med J—Vol 35, No I, 1987

8. Laurence J, Bmn-Veninet F, Schutzer SE, et al. Lymphadenopathy-associated viral antibody in AIDS: Immune correlations and definition of a carrier
state. N Engl J Med I984;311; 1269-73.
9. Centers for DLsease Control. Revision of the case definition of acquired
immunodeficiency syndrome for national reporting—United States. MM'WR
1985;34:373-5.
10. Esteban JI, Shi IV/-K, Tai G-C, Bodner AJ, Kay JWD, Alter HJ. Importance of Westem blot analysis in predicting infectivity of anti-HTLV-III/LAV
positive blood. Lancet 1985;2:1083-6.
11. Muirhead KA, Wallace PK, Schmitt TC, Frescatore RL, Franco JA,
Horan PK. Methodological considerations for implementation of lymphocyte
subset analysis in a clinical reference laboratory. Ann NY Acad Sci
1986;468:113-27.

T-Lymphocyte Studies in AIDS—Hayashi et al

